Shanghai, China, January 23, 2025 – WuXi XDC (stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (“CRDMO”) specializing in antibody drug bioconjugates (“ADCs”) and bioconjugates, has been awarded the Treasury Leadership Award for Best Liquidity Management by Standard Chartered.
This award underscores WuXi XDC’s commitment to financial excellence, reflecting its robust capabilities in maintaining financial stability, optimizing capital flows, and addressing complex financial challenges. It is a testament to the company’s dedication to delivering exceptional financial management practices.
WuXi XDC and Standard Chartered Bank have built a strong and enduring partnership that spans fund management, trade settlement, cross-border investment and financing, foreign exchange and hedging strategies, as well as capital markets activities. Standard Chartered is one of WuXi XDC’s most trusted financial partners, supporting operations in Chinese mainland, Hong Kong, and Singapore.
Michael Xi, CFO of WuXi XDC, stated,” We are honored to receive this prestigious award from Standard Chartered. With their innovative financial solutions, extensive global network, and expertise in trade finance, treasury managements, coupled with the strength of our professional teams across Chinese mainland, Hong Kong, and Singapore, Standard Chartered has been instrumental in providing the financial support needed for our business growth and capacity expansion in both domestic and international markets. This partnership empowers us to continue delivering world-class, end-to-end CRDMO services to our global clients.”
About WuXi XDC
WuXi XDC Cayman Inc. (“WuXi XDC” or the “Company”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com.
WuXi XDC Contacts
Investor：wuxixdc.ir@wuxibiologics.com
Media：wuxixdc_pr@wuxibiologics.com
BD：wuxixdc_info@wuxibiologics.com
About Us
Services & Solutions
Investor Relations
News & Resources
